Xtandi Oral Capsule, Liquid Filled 40Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

XTANDI: Oral capsule, liquid filled (40mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_18292.JPG
XTANDI 40mg Capsule
Astellas Pharma US, Inc.
Pill Identification: ENZ,MDV 

What is this Medicine?

ENZALUTAMIDE blocks the effect of the male hormone called testosterone. This medicine is used for certain types of prostate cancer.

In-Depth Information

XTANDI 40mg Capsule

NDC: 004690125
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Prostate Cancer

Storage Information
Store in a dry place
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
XTANDI 40mg Capsule
Drug Image file DrugItem_18292.JPG
Astellas Pharma US, Inc.
Pill Identification: ENZ,MDV 
Shape: capsule
Color: white

Reported Side Effects for XTANDI 40mg Capsule

Restless Legs Syndrome (RLS) Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Inability To Sleep Incidence:
<0.1%*
Severity: SEVERE
Onset: EARLY
Metallic Taste Incidence:
<0.1%*
Severity: SEVERE
Onset: EARLY
Hot Flashes Incidence:
<0.1%*
Severity: SEVERE
Onset: EARLY
Shortness Of Breath Incidence:
<0.6%*
Severity: SEVERE
Onset: EARLY
Constipation Incidence:
<0.7%*
Severity: SEVERE
Onset: DELAYED
Nose Bleed Incidence:
0.1%*
Severity: SEVERE
Onset: DELAYED
High Bilirubin Level Incidence:
0.1%*
Severity: SEVERE
Onset: DELAYED
Convulsions Incidence:
0.1-0.9%*
Severity: SEVERE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
0.2%*
Severity: SEVERE
Onset: DELAYED
Headache Incidence:
0.2-0.9%*
Severity: SEVERE
Onset: EARLY
Fluid Retention Incidence:
0.2-1.0%*
Severity: SEVERE
Onset: DELAYED
Hypoesthesia Incidence:
0.3%*
Severity: SEVERE
Onset: DELAYED
Lightheadedness Incidence:
0.3-0.5%*
Severity: SEVERE
Onset: EARLY
Loss Of Memory Incidence:
0.3%*
Severity: SEVERE
Onset: DELAYED
Decreased Thinking Incidence:
0.3%*
Severity: SEVERE
Onset: EARLY
Decreased Memory Incidence:
0.3%*
Severity: SEVERE
Onset: DELAYED
Decreased Appetite Incidence:
0.3%*
Severity: SEVERE
Onset: DELAYED
Nervousness Incidence:
0.3%*
Severity: SEVERE
Onset: DELAYED
Low Platelet Count Incidence:
0.3%*
Severity: SEVERE
Onset: DELAYED
Loose Stools Incidence:
0.3-1.1%*
Severity: SEVERE
Onset: EARLY
Balance Problems Incidence:
0.5%*
Severity: SEVERE
Onset: EARLY
Weight Loss Incidence:
0.8%*
Severity: SEVERE
Onset: DELAYED
Low White Blood Cells Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Muscle And/Or Bone Pain Incidence:
1.3%*
Severity: SEVERE
Onset: EARLY
Blood In The Urine Incidence:
1.3-1.8%*
Severity: SEVERE
Onset: DELAYED
Weakness Incidence:
1.5%*
Severity: SEVERE
Onset: EARLY
Joint Pain Incidence:
1.6-2.5%*
Severity: SEVERE
Onset: DELAYED
High Blood Pressure Incidence:
2.1-7.2%*
Severity: SEVERE
Onset: EARLY
Back Pain Incidence:
2.5-5.3%*
Severity: SEVERE
Onset: DELAYED
Tired Incidence:
3.4-9.0%*
Severity: SEVERE
Onset: EARLY
Gynecomastia Incidence:
3.4%*
Severity: MILD
Onset: DELAYED
Weakness Incidence:
3.4-9.0%*
Severity: SEVERE
Onset: DELAYED
Dry Skin Incidence:
3.5%*
Severity: MILD
Onset: DELAYED
Itching Incidence:
3.8%*
Severity: MILD
Onset: RAPID
Broken Bones Incidence:
4.0-8.8%*
Severity: SEVERE
Onset: DELAYED
Increased Urination Incidence:
4.8%*
Severity: MILD
Onset: EARLY
Paresthesias Incidence:
6.6%*
Severity: MILD
Onset: DELAYED
Inflamed Vocal Cords Incidence:
10.9-16.4%*
Severity: MILD
Onset: DELAYED
Sore Throat Incidence:
10.9-16.4%*
Severity: MILD
Onset: DELAYED
Rhinitis Incidence:
10.9-16.4%*
Severity: MILD
Onset: EARLY
Sinus Infection Incidence:
10.9-16.4%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

SECOND Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

THIRD Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with XTANDI

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5